Israel - English - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Israel - English - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Israel - English - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; calcium chloride dihydrate; glucose monohydrate; glucose monohydrate; magnesium chloride hexahydrate; magnesium chloride hexahydrate; sodium chloride; sodium chloride; sodium hydrogen carbonate; sodium hydrogen carbonate - solution for peritoneal dialysis - sodium chloride 11.57 g/l; calcium chloride dihydrate 0.5145 g/l; magnesium chloride hexahydrate 0.2033 g/l; glucose monohydrate 25.0 g/l; magnesium chloride hexahydrate 0.1017 g/l; calcium chloride dihydrate 0.2573 g/l; sodium hydrogen carbonate 2.940 g/l; sodium chloride 5.786 g/l; sodium hydrogen carbonate 5.880 g/l; glucose monohydrate 50.00 g/l - combinations of electrolytes - combinations of electrolytes - end-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.17/10/2017 בקשה לשינוי משטר מינון שינוי משטר מינון בהתאם למאושר באירופה

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; calcium chloride dihydrate; glucose as monohydrate; glucose monohydrate; magnesium chloride hexahydrate; magnesium chloride hexahydrate; sodium chloride; sodium chloride; sodium hydrogen carbonate; sodium hydrogen carbonate - solution for peritoneal dialysis - sodium chloride 11.57 g/l; calcium chloride dihydrate 0.5145 g/l; magnesium chloride hexahydrate 0.2033 g/l; glucose as monohydrate 93.50 g/l; glucose monohydrate 46.75 g/l; magnesium chloride hexahydrate 0.1017 g/l; calcium chloride dihydrate 0.2573 g/l; sodium hydrogen carbonate 2.940 g/l; sodium chloride 5.786 g/l; sodium hydrogen carbonate 5.880 g/l - combinations of electrolytes - combinations of electrolytes - end-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.17/10/2017 בקשה לשינוי משטר מינון שינוי משטר מינון בהתאם למאושר באירופה

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; calcium chloride dihydrate; glucose monohydrate; glucose monohydrate; magnesium chloride hexahydrate; magnesium chloride hexahydrate; sodium chloride; sodium chloride; sodium hydrogen carbonate; sodium hydrogen carbonate - solution for peritoneal dialysis - sodium chloride 11.57 g/l; calcium chloride dihydrate 0.5145 g/l; magnesium chloride hexahydrate 0.2033 g/l; sodium chloride 5.786 g/l; glucose monohydrate 33.0 g/l; glucose monohydrate 16.5 g/l; magnesium chloride hexahydrate 0.1017 g/l; calcium chloride dihydrate 0.2573 g/l; sodium hydrogen carbonate 2.940 g/l; sodium hydrogen carbonate 5.880 g/l - combinations of electrolytes - end-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.17/10/2017 בקשה לשינוי משטר מינון שינוי משטר מינון בהתאם למאושר באירופה

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 15 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; water for injections - dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.